加载中
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
收盘时
US$6.54
US$0.00 · 0.00%
盘后
US$6.54
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
日内区间
当前US$6.54
52周区间
当前US$6.54
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | 129.5万 USD | — | — |
| 毛利 | — | — | −129.5万 USD | — | — |
| 研究与开发 | 9030万 USD | 7330.2万 USD | 6393.7万 USD | 4223.8万 USD | 2516.1万 USD |
| 销售、一般及管理费用 | 2249.1万 USD | 2281.4万 USD | 1975.9万 USD | 1805.7万 USD | 1008.9万 USD |
| 营业费用 | 1.13亿 USD | 9611.6万 USD | 8369.6万 USD | 6029.5万 USD | 3525万 USD |
| 利息收入 | 663.1万 USD | 942.9万 USD | 858.8万 USD | 186.4万 USD | 1.3万 USD |
| 折旧和摊销 | 112.9万 USD | 122.3万 USD | 129.5万 USD | 117.7万 USD | 83.1万 USD |
| 营业利润 | −1.13亿 USD | −9611.6万 USD | −8499.1万 USD | −6029.5万 USD | −3525万 USD |
| 净利润 | −1.06亿 USD | −8691.9万 USD | −7640.8万 USD | −5876.3万 USD | −3525.1万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$17.50
上涨空间 167.58%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2124.86万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM943.62万0.01%787.4亿 USD0.19%US$277.88-0.38%
Vanguard Extended Market ETFVXF812.51万0.01%954亿 USD0.05%US$233.52-0.63%
State Street SPDR S&P Biotech ETFXBI604.07万0.06%98.74亿 USD0.35%US$151.4-1.54%
iShares Biotechnology ETFIBB337.79万0.03%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO326.05万0.02%139.17亿 USD0.24%US$353.71-0.86%
Dimensional - US Small Cap ETFDFAS217.8万0.01%338.69亿 USD0.31%US$78.17-0.23%
Fidelity Enhanced Small Cap ETFFESM216.91万0.03%64.1亿 USD0.28%US$45.24-0.48%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
